



an Open Access Journal by MDPI

# Antimicrobial Treatment of Lower Respiratory Tract Infections

Guest Editors: Message from the Guest Editors Prof. Dr. Anastasia Kotanidou Dear Colleagues, This Special Issue aims to delineate the latest pre-clinical Prof. Dr. Sotirios Tsiodras (experimental), animal and clinical research and clinic-Dr. Paraskevi C. Fragkou epidemiological data on the role of old and newer antimicrobials in the progress, prognosis and the outcome Dr. Charalampos D. of pneumonia. Ultimately, this issue aims to expand our Moschopoulos understanding and generate in-depth knowledge on the management of community- and healthcare-associated bacterial LRTIs through gathering current evidence and Deadline for manuscript addressing potential gaps in the literature. submissions: 30 June 2024 Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: antimicrobial treatment in community-acquired

in

treatment



mdpi.com/si/136437



pneumonia:

pneumonia/lower respiratory tract infection; antimicrobial healthcare-associated

epidemiology and mechanisms of antibiotic resistance of pneumonia pathogens; novel antibiotics for lower respiratory tract infections; use of antimicrobials for lower respiratory tract infections in specific populations, such as immunocompromised and critically ill patients, those with COVID-19 and other severe viral LRTIs and elderly, pediatric, cystic fibrosis, COPD and asthma patients.





an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supragovernmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

Antibiotics Editorial Office MDPI, St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/antibiotics antibiotics@mdpi.com X@antibioticsmdpi